TP53 and neoplasm: The concomitant upregulation of CAD with loss of a key effector of p53-mediated tumour suppression leading to a loss of the efficaciousness of PALA is an interesting avenue to explore for targeting the pyrimidine ribonucleotide synthetic pathway.